Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, MyelomaMarch 25, 2024
European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaMarch 21, 2024
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, MyelomaMarch 8, 2024
EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaFebruary 23, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPEFebruary 13, 2024
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaJanuary 30, 2024
MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
